Find a Tender
complete
Official procurement procedure
(NU/1433-30) CAF1 - A robust, easily engineered polymer with applications in synthetic biology: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation
Business and management consultancy and related services
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Newcastle University: "(NU/1433-30) CAF1 - A robust, easily engineered polymer with applications in synthetic biology: Commercialisation of university research through provision of management skills to assist in successful spin-out company creation". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Newcastle University | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Newcastle University
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Newcastle University. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Competition Density
2.4Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 104 active published awards; 98 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNewcastle University | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSDynamic market | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published6 May 2022, 13:20 BST | Last source update6 May 2022, 13:20 BST | Recurring procurementNot published |
ClassificationBusiness and management consultancy and related services | ||
Delivery area | ||
OCIDocds-h6vhtk-0334e1 | ||
What is being bought
Caf1 is secreted from the bacterium Yersinia pestis to protect it from white blood cells during infection. It is formed from 15 kDa monomers that produce robust, flexible polymers up to 2 µm in length. We aim to create a spinout company that will initially produce Caf1 polymers and coated plasticware/microcarriers for the 2D cell culture market, predominantly focussed on laboratory research, expanding into commercial companies looking to scale up cell production. The Newcastle-based company will supply these products directly to customers, and through marketing partners who have established distribution networks. We are looking for a CEO/COO/Chairperson to work alongside Daniel Peters to develop a business plan that has considered the best market strategy for Caf1 in preparation for spinout formation and achieving the necessary fundraising
The initial brief of the executive will be to:
(1) Work with the existing team to lead in the creation of a viable 5 year business plan;
(2) Obtain university approval for the venture;
(3) a. Act for the company in the spin-out legal process and address all company formation matters;
b. Obtain founder academics’ and Newcastle University (including the Head of Company Creation) approval for appointment as CEO or agreed post supporting Daniel Peters
c. Provide to the appropriate university all matters necessary for Research England reporting requirements;
(4) Leading and work alongside the existing team to secure start up funding (venture capital and other) funding
Stage (5) will produce the funds by which the new start-up company can consider employing the executive going forward. It is expected, and the intent of the scheme, that the Executive will remain with the business following the end of the contract period. However, such appointment will be at the discretion of the board and appropriate university and will be subject to confirmation, typically at Stage 4 above
What changed
From the official release history
- Status changed to complete
6 May 2022, 13:20 BST - Official notice release published
6 May 2022, 13:20 BST - Buyer information updated
6 May 2022, 13:20 BST
Lots and requirements (1)
Published by the contracting authority
- Lot 1 · #1Individual lot title not publishedcancelledPublished valueNot publishedCaf1 is secreted from the bacterium Yersinia pestis to protect it from white blood cells during infection. It is formed from 15 kDa monomers that produce robust, flexible polymers up to 2 µm in length. We aim to create a spinout company that will initially produce Caf1 polymers and coated plasticware/microcarriers for the 2D cell culture market, predominantly focussed on laboratory research, expanding into commercial companies looking to scale up cell production. The Newcastle-based company will supply these products directly to customers, and through marketing partners who have established distribution networks. We are looking for a CEO/COO/Chairperson to work alongside Daniel Peters to develop a business plan that has considered the best market strategy for Caf1 in preparation for spinout formation and achieving the necessary fundraising The initial brief of the executive will be to: (1) Work with the existing team to lead in the creation of a viable 5 year business plan; (2) Obtain university approval for the venture; (3) a. Act for the company in the spin-out legal process and address all company formation matters; b. Obtain founder academics’ and Newcastle University (including the Head of Company Creation) approval for appointment as CEO or agreed post supporting Daniel Peters c. Provide to the appropriate university all matters necessary for Research England reporting requirements; (4) Leading and work alongside the existing team to secure start up funding (venture capital and other) funding Stage (5) will produce the funds by which the new start-up company can consider employing the executive going forward. It is expected, and the intent of the scheme, that the Executive will remain with the business following the end of the contract period. However, such appointment will be at the discretion of the board and appropriate university and will be subject to confirmation, typically at Stage 4 aboveContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
6 May 2022, 13:20 BST - Award active
Not published · Not published - Contract active
Signed 12 Apr 2022, 00:00 BST · £29,500
Commercial outcome and competition
Awards KWWK Ltd Not published · Not published · active |
Contracts Contract £29,500 · signed 12 Apr 2022, 00:00 BST · active |
Bid statistics bids: 4 (lot 1) electronicBids: 4 (lot 1) foreignBidsFromEU: 0 (lot 1) foreignBidsFromNonEU: 4 (lot 1) smeBids: 4 (lot 1) |
Buyer and organisations in this procedure
Newcastle University
Contracting authority GB-FTS-168Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published
Planning and rationale
Planning budgetNot published |
No-engagement rationaleNot published |
Procedure rationaleNot published |